## Review setup
- **Input scope** Full manuscript text (Abstract, Introduction, Methodology, Results, Discussion, Conclusion)
- **Assessment boundary** Scientific soundness, methodological rigor, validity of conclusions relative to evidence, and suitability for publication
- **Shared manuscript claim summary** The authors apply an integrated structure-based computational workflow to prioritize Emodin-8-glucoside as a candidate ligand for the VEGFR1 kinase domain, using docking, molecular dynamics, end-point energy calculations, and ADMET predictions, within the exploratory context of placenta previa.
- **Visible evidence base** Abstract, full Methods, Results, Discussion, Conclusion, figure and table references
- **Missing materials affecting confidence** Figures 1-13, Tables 1-11, Supporting Information S1 Table, and the supplementary dataset are referenced but not provided. This limits verification of quantitative results and interaction analyses.

## Reviewer
- **Overall assessment** This manuscript presents a computationally driven candidate prioritization study with a commendable degree of methodological transparency and a careful, appropriately hedged interpretation of results. The authors consistently distinguish between computational prediction and experimental validation, and they explicitly acknowledge the exploratory nature of their findings. However, the scientific impact is limited by the absence of experimental confirmation, the reliance on a single MD trajectory per complex, and the modest concordance between the two docking programs. The manuscript is technically sound in its execution but does not establish a novel biological or therapeutic claim beyond what computational screening can offer. The relevance to placenta previa is contextual rather than mechanistic, and the authors correctly avoid overstating this connection. The work may be of interest to a specialized audience in computational drug discovery, but its broader significance is constrained by the lack of functional validation.

- **Who would be interested in the results, and why** Computational chemists and structural biologists working on kinase-targeted drug discovery may find the integrated workflow and the comparative analysis of docking and MD methods useful. Researchers investigating natural products as lead scaffolds, particularly anthraquinone glycosides, may also be interested. However, clinicians and translational researchers in obstetrics are unlikely to find actionable insights, as the study does not provide evidence of biological activity, selectivity, or safety in pregnancy-relevant models.

- **Major strengths** 
  1. The authors demonstrate a rigorous and transparent computational workflow, including explicit validation of the docking protocol via redocking with RMSD assessment.
  2. The interpretation of results is consistently cautious and appropriately hedged, with clear statements about what the computational data can and cannot establish.
  3. The use of two independent docking programs and the reporting of their concordance adds methodological credibility.
  4. The authors explicitly address the distinction between placenta previa and related conditions, avoiding inappropriate extrapolation from other obstetric syndromes.
  5. The limitations section is thorough and candid, particularly regarding the single MD trajectory and the small number of snapshots used for end-point energy estimates.

- **Major Concerns**

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The manuscript claims that Emodin-8-glucoside is "consistently prioritized among the highest-ranked compounds" and that MD simulations showed "persistent binding-site association."
- **Evidence pointer** Results section, Tables 2, 5-9, Figures 7-12 (location not provided)
- **Concern** The central claim of persistent binding is based on a single 500 ns MD trajectory per complex, as explicitly acknowledged by the authors. Without replicate simulations with different initial velocity seeds, the observed stability metrics (RMSD, RMSF, hydrogen bonds, interaction energies) cannot be distinguished from trajectory-specific artifacts. The authors acknowledge this limitation but do not address it methodologically. Additionally, the MM-PBSA result for Emodin-8-glucoside is near-zero with substantial variability, which undermines the claim of favorable binding energetics under that model. The manuscript does not provide a criterion for what constitutes "persistent" association beyond qualitative inspection of distance plots.
- **Why it matters** The central conclusion that Emodin-8-glucoside is a viable candidate for experimental testing rests on the assumption that the computationally predicted binding mode is stable and energetically plausible. A single trajectory and method-dependent energy estimates do not provide sufficient evidence to prioritize this compound over the many other phytochemicals that were not subjected to MD. Without replicate simulations and convergence analysis, the claim of persistent binding is not robustly supported.
- **Resolution test** The authors should perform at least three independent MD simulations with different initial velocity seeds for each complex and report the mean and standard deviation of key metrics across replicates. They should also assess convergence using block averaging or similar methods. If the MM-PBSA estimate remains near-zero across replicates, the claim of favorable binding should be revised to reflect the method-dependence of the result.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Relevance of context
- **Claim pointer** The manuscript frames the study in the context of placenta previa and suggests that VEGFR1 kinase domain is a candidate molecular target for this condition.
- **Evidence pointer** Introduction, Discussion (location not provided)
- **Concern** The connection between VEGFR1 kinase activity and placenta previa is not established by any data presented in this study. The authors correctly state that placenta previa tissue studies have reported altered VEGF expression and vascular morphology, but they do not demonstrate increased VEGFR1 kinase activity in this condition. The manuscript does not provide any placenta previa-specific molecular data, patient samples, or disease models. The contextual framing is therefore speculative, and the relevance of the computational findings to placenta previa is not supported by evidence.
- **Why it matters** The title and framing imply a disease-relevant investigation, but the study is purely a computational screening exercise. If the connection to placenta previa is not evidence-based, the significance of the work is substantially reduced, and the framing may mislead readers about the translational relevance of the findings.
- **Resolution test** The authors should either (a) provide evidence from the literature or preliminary data that VEGFR1 kinase activity is relevant to placenta previa pathogenesis, or (b) reframe the manuscript as a general computational exploration of VEGFR1-binding phytochemicals, with placenta previa mentioned only as a hypothetical future application. The current framing overstates the disease relevance.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** Methodological validation
- **Claim pointer** The authors state that the redocking of 8ST reproduced its experimental pose with a heavy-atom RMSD of 1.465 Å, which is used to validate the docking protocol.
- **Evidence pointer** Results section, Figure 6 (location not provided)
- **Concern** While the RMSD of 1.465 Å is below the 2.0 Å threshold, this validation is limited to a single ligand. The manuscript does not report whether the docking protocol was validated against a set of known VEGFR1 inhibitors or whether the scoring functions were benchmarked for this specific target. The moderate Spearman correlation (rho = 0.553) between VINA and MOE rankings suggests that the two methods do not strongly agree, which raises questions about the reliability of the prioritization.
- **Why it matters** The prioritization of Emodin-8-glucoside depends on the reliability of the docking scores. A single-ligand redocking validation is insufficient to establish that the protocol is robust for the diverse set of 21 phytochemicals tested. The moderate inter-method concordance further weakens confidence in the ranking.
- **Resolution test** The authors should validate the docking protocol using a set of known VEGFR1 kinase inhibitors with experimentally determined binding affinities, reporting enrichment factors or similar metrics. They should also discuss the implications of the moderate VINA-MOE correlation for the robustness of the prioritization.

- **Minor Comments**

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract
- **Evidence pointer** Abstract (location not provided)
- **Issue** The abstract states that Emodin-8-glucoside "represents an in-silico-prioritized exploratory candidate requiring biochemical, selectivity, placental-cell, and pregnancy-safety validation." This is appropriately cautious, but the abstract does not mention the method-dependent nature of the end-point energy estimates or the lack of replicate MD simulations. A reader relying solely on the abstract may overestimate the strength of the computational evidence.
- **Required correction** Add a brief statement in the abstract acknowledging that the computational predictions require experimental confirmation and that the binding energetics were method-dependent.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Reproducibility
- **Affected element** Methods, MD simulation section
- **Evidence pointer** Methods, "Molecular dynamics simulation studies" (location not provided)
- **Issue** The manuscript does not report the software version for the AMBER force field parameterization beyond "AmberTools25," nor does it specify the exact commands or parameter files used for the MM-GBSA and MM-PBSA calculations. This limits reproducibility.
- **Required correction** Provide a detailed description of the parameterization workflow, including specific AmberTools module versions, and consider depositing input files and parameter files in a public repository.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Data presentation
- **Affected element** Results, ADMET section
- **Evidence pointer** Results, "ADMET analysis of Emodin-8-glucoside" (location not provided)
- **Issue** The ADMET predictions are presented as a list of individual properties, but the implications of these predictions for the compound's drug-likeness are not discussed in a integrated manner. For example, the low gastrointestinal absorption and P-glycoprotein substrate status are noted, but the authors do not discuss how these properties would affect the feasibility of oral administration or the need for alternative delivery routes.
- **Required correction** Add a brief discussion of the integrated ADMET profile and its implications for the compound's developability, including potential formulation strategies or route-of-administration considerations.

- **Technical failings that need to be addressed before the case is established** 
  1. Single MD trajectory per complex without replicate simulations (R1-M1).
  2. Lack of evidence linking VEGFR1 kinase activity to placenta previa pathogenesis (R1-M2).
  3. Insufficient validation of the docking protocol beyond a single redocking test (R1-M3).

- **Assessment against Nature-style criteria** 
  - **Originality**: Moderate. The application of a combined docking-MD-ADMET workflow to a specific compound is not methodologically novel, but the specific target-compound combination has not been previously reported.
  - **Scientific importance**: Low to moderate. The study does not establish a new biological mechanism, therapeutic target, or clinical insight. Its value is primarily as a hypothesis-generating exercise.
  - **Interdisciplinary readership**: Limited. The work is likely to appeal mainly to computational chemists and structural biologists. The clinical relevance to obstetrics is not established.
  - **Technical soundness**: Adequate with reservations. The methods are generally appropriate, but the lack of replicate simulations and limited validation reduce confidence in the conclusions.
  - **Readability for nonspecialists**: Good. The manuscript is clearly written, and the authors make a commendable effort to explain the limitations of computational approaches for a broader audience.

- **Recommendation posture** Currently not established from the provided evidence. The manuscript is technically competent but does not provide sufficient evidence to support the central claim that Emodin-8-glucoside is a prioritized candidate for VEGFR1 targeting in placenta previa. The lack of replicate simulations, the method-dependent energetics, and the unestablished disease relevance are significant gaps. The authors should address these concerns and consider reframing the manuscript to more accurately reflect the exploratory and hypothesis-generating nature of the work.

## Risk / unsupported claims
- The claim that Emodin-8-glucoside shows "persistent binding-site association" is not robustly supported due to the single MD trajectory and method-dependent energy estimates.
- The relevance of VEGFR1 kinase inhibition to placenta previa is asserted as a context but is not supported by any data presented in this study.
- The ADMET predictions, while appropriately labeled as computational, include several active toxicity endpoints that are not discussed in terms of their potential impact on the compound's viability as a therapeutic candidate.
- The statement that Emodin-8-glucoside was "consistently prioritized" across methods is weakened by the moderate Spearman correlation (rho = 0.553) between the two docking programs.